Endo Hirsutism Pelvic Us Severe Progressive Hyperandrogen
ASecurity
Perform pelvic ultrasonography to detect ovarian neoplasm in patients with severe or progressive hyperandrogenism, triggered by moderate/severe hirsutism, virilization, or rapid hair growth despite therapy. Third-person guidance for clinicians to gather data, rule in/out indication, classify findings, and decide next steps.
Installs into .claude/skills of the current project.
Are you the author of Endo Hirsutism Pelvic Us Severe Progressive Hyperandrogen?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-hirsutism-pelvic-us-severe-progressive-hypera)
---
name: endo-hirsutism-pelvic-us-severe-progressive-hyperandrogen
description: Perform pelvic ultrasonography to detect ovarian neoplasm in patients with severe or progressive hyperandrogenism, triggered by moderate/severe hirsutism, virilization, or rapid hair growth despite therapy. Third-person guidance for clinicians to gather data, rule in/out indication, classify findings, and decide next steps.
---
# Perform pelvic ultrasonography to detect ovarian neoplasm in severe or progressive hyperandrogenism
## STEP 1 — Gather Information
Collect: hirsutism severity (Ferriman–Gallwey score), tempo of progression (weeks/months), signs of virilization (clitoromegaly, deepened voice, increased muscle mass), menstrual pattern, infertility, galactorrhea, central obesity, acanthosis nigricans, medication history (androgens, valproic acid, GnRH agonists), prior labs (total/free testosterone, DHEAS, 17‑OHP), pregnancy status, and family history of endocrine tumors or Cushing.
## STEP 2 — Rule In / Rule Out
If patient has moderate/severe hirsutism (FG ≥15), rapid‑progression hirsutism, or clinical virilization **or** hirsutism progressing despite adequate anti‑androgen/OC therapy → **Proceed to pelvic US**.
If hirsutism is mild, stable, and no virilization or progression → **Consider alternative etiologies**; pelvic US for neoplasm not routinely indicated.
## STEP 3 — Classify or Stratify
Interpret transvaginal pelvic US:
- **Low suspicion**: normal ovarian volume, no discrete mass, simple cysts <3 cm, typical PCO morphology.
- **High suspicion**: solid or complex mass >3 cm, irregular borders, increased vascularity on Doppler, ascites, or concerning for ovarian hyperthecosis (absent follicles with stromal hyperreactivity).
## STEP 4 — Decide
- **High suspicion**: Refer urgently to gynecologic oncology or surgical oncology for further imaging (MRI/CT) and possible excision.
- **Low suspicion**: Reassess clinically; if hyperandrogenism persists, pursue adrenal workup (CT adrenal, 17‑OHP stimulation) or repeat US in 3–6 months if clinical concern rises.
## Clinical Guardrails / Mimics / Pitfalls
Do **not** rely on a normal US to exclude neoplasm when clinical suspicion remains high (small androgen‑secreting tumors may be <2 cm). Avoid using US as a first‑line test in mild hirsutism without progression. Remember that ovarian hyperthecosis can mimic neoplasm; correlate with histology if uncertain. Always rule out pregnancy before interventions. Do not repeat US frequently without change in clinical picture.
## Concrete Clinical Example
A 30‑year‑old woman presents with 4‑month history of rapidly worsening facial and chest hair (FG 24), new clitoromegaly, and normal total/free testosterone. Transvaginal US reveals a 3.8 cm solid left ovarian lesion with increased intratumoral flow. She is referred for laparoscopic oophorectomy; pathology shows a Sertoli‑Leydig cell tumor secreting testosterone.
**Source:** Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-00241